ACC 2019 News: ADVANCE Registry Outcomes

Coming out of this year’s American College of Cardiology (ACC) meeting, it’s clear that there is growing consensus for using coronary computed tomography angiography (CCTA) as a primary diagnostic strategy for assessing symptomatic patients with coronary artery disease (CAD). There were numerous discussions about whether the 2016 National Institute of Health and Care Excellence (NICE) guidelines putting CCTA as the first test for all stable chest pain patients should be universally adopted, following the recent publications by Hecht, et al in the European Heart Journal and Blaha, et al in the Journal of the American College of Cardiology (JACC). The discussions I engaged in certainly indicated there is no doubt the evidence supports putting CCTA as the frontline test for stable chest pain.

I was also encouraged to see that the CT manufacturers are offering new solutions such as CT scanners that are optimized for cardiac scanning and are compact enough to be housed in outpatient offices. These new offerings will help make CCTA more broadly available.

Specific to the HeartFlow FFRCT Analysis, I wanted to share two new presentations which demonstrate the value of following a CCTA and HeartFlow Analysis pathway.

ADVANCE Registry One-Year Outcomes (JACC Imaging publication)

ADVANCE is a large prospective international multicenter registry that included 5,083 patients at 38 sites, split between North America, the EU, and Japan. In the study, all patients underwent a CCTA. If additional information was needed, the physician ordered a HeartFlow Analysis. The 1-year results showed that the HeartFlow Analysis helped physicians more precisely stratify their patients and deliver more personalized care:

FFRCT to Assess Coronary Artery Disease – Sanger Heart Experience

During the value-based healthcare session, Dr. Geoffrey Rose of the Sanger Heart & Vascular Institute presented the findings of incorporating the HeartFlow Analysis in their center. Sanger adopted the HeartFlow Analysis and found the following:

FFR<sub>CT</sub> ACC 2019

Download PDF

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.